Sanofi named a new chief scientific officer this week, part of a series of moves aimed at redefining the company.

After a few years in biotech, Mike Quigley, Ph.D., is returning to the pharma fold, taking up the top science spot at Sanofi.

Sanofi has appointed Mike Quigley, a former executive at Gilead and Bristol Myers Squibb, as the French pharma's next chief ...

Regeneron and Sanofi have announced that the FDA has expanded the label of megablockbuster Dupixent to treat COPD. The approval brings the versatile drug’s count of U.S. indications up to six ...

NEW YORK, Sept 23 (Reuters) - Sanofi's (SASY.PA), opens new tab chief executive, Paul Hudson, said in an interview on Monday that the company is poised for strong growth from a variety of new ...

Sept 27 (Reuters) - The U.S. Food and Drug Administration has approved Sanofi (SASY.PA), opens new tab and Regeneron's (REGN.O), opens new tab blockbuster drug Dupixent for patients with a chronic ...

said Frankel, who used to work for one of the caucus’ three co-chairs, Rep. Mike Quigley (D-Ill.). “I think it’s really important for SEEC to justify why it’s an important piece of the ...

Rep. Mike Quigley (D-Ill.) said Biden “has to be honest with himself” and warned that his decision to run for reelection could hurt Democrats down the ballot. “We have to be honest with ours ...

CHICAGO — Illinois Rep. Mike Quigley on Friday became the first high-profile Democrat in the state and the fourth member of ...

METHODOLOGY: The numbers on this page are calculated from contributions of more than $200 from individuals, as reported to the Federal Election Commission. PAC dollars are not included. NOTE: All the ...

(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY), Friday announced that the U.S. Food and Drug Administration has approved Dupixent as an add-on maintenance treatment of adults ...